Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab

Technology appraisal guidance
Reference number: TA612
Published: 20 November 2019

History

Documents created during the development process.

Expected publication

Equality Impact Assessment (Guidance development) (PDF 158 KB)

Published:

20 November 2019

Declaration of interests

Register of interests (PDF 122 KB)

Published:

20 September 2019

Final draft guidance

Final draft guidance
Final appraisal document (PDF 243 KB)

Published:

17 October 2019
Committee papers (PDF 524 KB)

Published:

17 October 2019
Public committee slides (PDF 320 KB)

Published:

17 October 2019

Draft guidance

Draft guidance
Appraisal consultation document (online commenting)
Committee papers (PDF 13.88 MB)

Published:

07 August 2019
Public committee slides (PDF 990 KB)

Published:

07 August 2019
Appraisal consultation document (PDF version) (PDF 254 KB)

Published:

07 August 2019

Invitation to participate

Final scope (PDF 227 KB)

Published:

16 November 2018
Final stakeholder list (PDF 299 KB)

Published:

16 November 2018
NICE's response to comments on the draft scope and provisional stakeholder list (PDF 226 KB)

Published:

16 November 2018
Equality impact assessment (Scoping) (PDF 129 KB)

Published:

16 November 2018

Draft scope documents

Provisional matrix (post-referral) (PDF 299 KB)

Published:

19 October 2018
Consultation document draft scope (PDF 234 KB)

Published:

19 October 2018